Home MarketAlkem Laboratories Ltd.

Alkem Laboratories Ltd. Stock Info: As on 2018-05-24 15:45:14

Nse

1957.55

-7.80(-0.40%)
Change%
52 Week Range
1,578.30
11.00
2,469.00
10.00
Open1,956.75
Day's Range1,572.28 - 2,358.42
Value Traded (in ₹ Cr.) 2.58

Bse

1938.45

-19.80(-1.01%)
Change %
52 Week Range
1,578.00
11.00
2,468.00
10.00
Open1,955.20
Day's Range1,566.60 - 2,349.90
Value Traded (in ₹ Cr.) 2.13

Stock Exchange

Category No. Of Shares Share %
ForeignPromoters 0.00 0.00%
IndianPromoters 78,743,333.00 65.86%
Mutual Funds/UTI 3,465,569.00 2.90%
FII 4,308,479.00 3.60%
Employee 0.00 0.00%
Public 30,390,307.00 25.42%
Government 0.00 0.00%
Others 2,158,937.00 1.81%
More

Key Statistics

Valuation Measures
Market Cap / Sales Ratio 5.65
Basic EPS (Rs.) 73.86
Cash EPS 80.27
BVPerShare Excl 367.43
Operating Revenue 390.50
PBDITPerShare 83.19
Dividend 6.00
NPPerShare 73.87
Current Ratio 1.59
Quick Ratio 0.98
PriceToBV 6.01
Earnings 0.03
PBDIT Margin 21.30
PBT Margin 19.15
NP Margin 18.91
Return On Assets 14.97
Retention Ratios 91.87
Parameter Mar-17 (₹ Cr.) Yoy%change
Total Income 4,785.05
Total Expenses 3,890.62
EBITDA 994.59
PBT 894.43
PAT 883.16
Net Income 883.16
More
Parameter Sep-17 (₹ Cr.) 6M % change
Total Income 2,739.24
Total Expenses 2,150.45
EBITDA 539.62
PBT 569.96
PAT 442.88
Net Income 0.00
More
Total Assets
Total Assets
Parameter Mar-17 (₹ Cr.) Yoy%change
Total share capital 23.91
Net worth 4,392.65
Investments 1,517.64
Total Liability 5,898.35
Total debt 368.23
Net block 1,344.07
Total Assets 5,898.35
Parameter Sep-17 (₹ Cr.) 6M % change
Total share capital 23.91
Net worth 3,472.04
Investments 1,063.05
Total Liability 5,118.18
Total debt 872.21
Net block 987.26
Total Assets 5,118.18
Company Curr Price Prev. Close Change% W's Low/High

Aarti Drugs Ltd.

533.05 531.95 0.21
524.95580

Abbott India Ltd.

6671.7 6587.45 1.28
65106890

Ajanta Pharma Ltd.

977.6 987 -0.95
962.351074.5

Albert David Ltd.

362.35 362.75 -0.11
356.2383.15

Alembic Ltd.

48.85 50.8 -3.84
50.254

Alembic Pharmaceuticals Ltd.

420.7 422.3 -0.38
418.5491.2

Alpa Laboratories Ltd.

32.1 32.55 -1.38
31.5534.4
Company Curr Price Prev. Close Change% W's Low/High

Aarey Drugs & Pharmaceuticals Ltd.

47.5 49.05 -3.16
46.351.55

Aarti Drugs Ltd.

530 529.15 0.16
526585

Aayush Food & Herbs Ltd.

47.7 48.1 -0.83
4355

Abbott India Ltd.

6699.95 6593.7 1.61
6465.056872.5

ABL Bio-Technologies Ltd.

0.81 0.78 3.85
0.750.81

Addlife Pharma Ltd.

0.46 0 0
0.460.5

Adinath Bio-Labs Ltd.

0.3 0.31 -3.23
0.30.3
More
Parameter Mar-17(in ₹ Cr.)
Cash from operating activities 496.48
Cash from investing activities -361.90
Cash from financing activities -122.06
Net change in cash 12.52

Stock Held By Mutual Fund Schemes

Scheme Holding (%)
Motilal Oswal Multicap 35 Fund 2.26%
DSP BlackRock Mid Cap Fund 1.47%
Reliance Growth Fund 1.14%
DSP BlackRock Equity & Bond Fund 0.95%
SBI Healthcare Opportunities Fund 6.25%
DSP BlackRock Equity Opportunities Fund 1.03%

M Venkatesh appointed MRPL MD

M Venkatesh has been appointed as the Managing Director of Mangalore Refineries and Petrochemicals Limited (MRPL), an order issued by the Personnel Ministry said today. Vekatesh is at present Director (Refineries) in the MRPL, a subsidiary of the Oil and Natural Gas Corporation Limited (ONGC) He has been appointed to the post for a period of five years with effect from the date of his assumption of charge of the post on or after June 1, 2018, or till the date of his superannuation, the order said.

24-05-2018 11:42

TCS expands operations in Florida as part of Transamerica deal

India's largest IT services firm TCS today said it has expanded operations in Florida, US, with over 430 employees joining the company as part of its deal with Transamerica. In January, Tata Consultancy Services (TCS) had signed an over USD 2 billion deal with Transamerica to administer the latter's life insurance, annuity, supplemental health insurance, and workplace voluntary benefits products. It covered managing administration of more than 10 million policies. More than 430 former Transamerica employees now work for TCS at this new St Petersburg facility (in Florida) as part of recruiting and investing in more than 2,200 Transamerica jobs across the US in multiple locations, the Indian software services giant said in a statement. TCS will occupy several floors of Transamerica's building at 570 Carillon Parkway in St Petersburg, as part of a multi-year agreement with Transamerica... The St Petersburg office is a new US business centre for TCS, adding to the over 1,000 employees already serving American businesses throughout the state, it added. TCS said it has invested nearly USD 3 billion in the US over the past three years and has been among the top two IT services job creators in the country. TCS is a leading industry employer in the US, striving to help American companies like Transamerica to digitally transform their business and capitalise on rapidly evolving customer demands, TCS President and Global Head (Banking, Financial Services and Insurance Platforms) Suresh Muthuswami said. We look forward to partnering with St Petersburg's city, state and local organizations to further build upon our business and community impact, he added. The company said it has made tremendous community impact in Florida over past several years.

24-05-2018 11:16

Kotak India Growth Fund Series 4 - Direct Plan: change in investment factsheets for April

Kotak India Growth Fund Series 4 - Direct Plan has announced change in investment factsheets and fund flash for the month ended April 30, 2018. As on Apr 30, 2018, the total size of the Fund was Rs 429.99 crores, compared with Rs 424.96 crores in the last month. The Fund's NAV per unit was Rs 9.89 for Growth, while 52-Week High and Low ranges were Rs 10.35 and Rs 9.51 respectively. The Equity - Diversified fund with Growth plan was launched on Jan 29, 2018 and managed by Fund Managers Harsha Upadhyaya, Devender Singhal. The top five companies based on a percentage of total holdings were ITC Ltd. (35.18 Cr.), HDFC Bank Ltd. (19.44 Cr.), Mahindra & Mahindra Ltd. (19.21 Cr.), Tata Motors Ltd. (17.02 Cr.) and Bata India Ltd. (16.05 Cr.). Kotak India Growth Fund Series 4 - Direct Plan is promoted by Kotak Mahindra Mutual Fund and managed by Kotak Mahindra Asset Management Company Ltd..

24-05-2018 11:00

Kotak India Growth Fund Series 4: change in investment factsheets for April

Kotak India Growth Fund Series 4 has announced change in investment factsheets and fund flash for the month ended April 30, 2018. As on Apr 30, 2018, the total size of the Fund was Rs 429.99 crores, compared with Rs 424.96 crores in the last month. The Fund's NAV per unit was Rs 9.88 for Growth, while 52-Week High and Low ranges were Rs 10.34 and Rs 9.51 respectively. The Equity - Diversified fund with Growth plan was launched on Jan 29, 2018 and managed by Fund Managers Harsha Upadhyaya, Devender Singhal. The top five companies based on a percentage of total holdings were ITC Ltd. (35.18 Cr.), HDFC Bank Ltd. (19.44 Cr.), Mahindra & Mahindra Ltd. (19.21 Cr.), Tata Motors Ltd. (17.02 Cr.) and Bata India Ltd. (16.05 Cr.). Kotak India Growth Fund Series 4 is promoted by Kotak Mahindra Mutual Fund and managed by Kotak Mahindra Asset Management Company Ltd..

24-05-2018 11:00

BLS International to assist Sopra Steria on UK visa renewals

Visa service provider BLS International today said theUnited Kingdom Visas and Immigration (UKVI) has awarded Sopra Steria a new contract to enable visa renewals for those individuals who are already in the UK. BLS International will support Sopra Steria and UKVI, a division of the UK Home Office responsible for deciding who can visit and stay within the UK, by establishing and delivering some of the key add value services under the contract, it said in a release. BLS International claims to handle about 12 million visa applications annually across the globe at present. Meanwhile, shares of the company were trading at Rs 172.55 apiece, up 1 per cent from the previous close at 10:50 hours on BSE.

24-05-2018 10:51

Alkem Laboratories - Analysts/Institutional Investor Meet/Con. Call Updates

Alkem Laboratories Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates

23-May-2018 03:31 PM

Alkem Laboratories - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

With reference to relevant provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we write to inform you that a conference call to discuss the Q4FY18 and FY18 financial results will be held on Wednesday, 30th May, 2018 at 5.00 P.M.

Please find attached herewith the conference call details.

Kindly take note of the same.

23-May-2018 03:29 PM

Alkem Laboratories - Board to consider Final Dividend

Alkem Laboratories Ltd has informed BSE that a meeting of the Board of Directors of the Company is scheduled to be held on May 30, 2018, inter alia:

1. To consider and approve the Standalone and Consolidated Audited Financial Results of the Company for the quarter and financial year ended March 31, 2018; and

2. To consider and recommend Final Dividend, if any, for the Financial Year ended March 31, 2018.

22-May-2018 06:50 PM

Alkem Laboratories - Notice Of Meeting Of Board Of Directors Of Alkem Laboratories Limited ('Company')

Notice is hereby given to the Stock Exchanges under Regulation 29 read with Regulation 33 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 that a meeting of the Board of Directors of the Company is scheduled to be held on Wednesday, 30th May, 2018, inter alia,

(i) to consider and approve the Standalone and Consolidated Audited Financial Results of the Company for the quarter and financial year ended 31st March, 2018; and

(ii) to consider and recommend Final Dividend, if any, for the Financial Year ended 31st March, 2018.

22-May-2018 06:43 PM

Alkem Laboratories - Disc. under Reg.30 of SEBI (SAST) Reg.2011

Premlata Singh has submitted to the Exchange a copy of disclosure under Regulation 30(1) and 30(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

17-Apr-2018 02:54 PM

Alkem Laboratories - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

With reference to relevant provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we write to inform you that a conference call to discuss the Q4FY18 and FY18 financial results will be held on Wednesday, 30th May, 2018 at 5.00 P.M.

Please find attached herewith the conference call details.

Kindly take note of the same.

23-May-2018 03:29 PM

Alkem Laboratories - Board to consider Final Dividend

Alkem Laboratories Ltd has informed BSE that a meeting of the Board of Directors of the Company is scheduled to be held on May 30, 2018, inter alia:

1. To consider and approve the Standalone and Consolidated Audited Financial Results of the Company for the quarter and financial year ended March 31, 2018; and

2. To consider and recommend Final Dividend, if any, for the Financial Year ended March 31, 2018.

22-May-2018 06:50 PM

Alkem Laboratories - Notice Of Meeting Of Board Of Directors Of Alkem Laboratories Limited ('Company')

Notice is hereby given to the Stock Exchanges under Regulation 29 read with Regulation 33 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 that a meeting of the Board of Directors of the Company is scheduled to be held on Wednesday, 30th May, 2018, inter alia,

(i) to consider and approve the Standalone and Consolidated Audited Financial Results of the Company for the quarter and financial year ended 31st March, 2018; and

(ii) to consider and recommend Final Dividend, if any, for the Financial Year ended 31st March, 2018.

22-May-2018 06:43 PM

Corporate Details

About Management

The Company was incorporated as a private limited company `Alkem Laboratories Private Limited' on August 8,1973 at Patna under the Companies Act, 1956 and subsequently became a deemed public limited company under section 43A(2) of Companies Act, 1956 on October 26, 1988. Pursuant to the Company passing a resolution under section 21 of Companies Act, 1956 and upon issuance of a fresh certificate of incorporation consequent on change of name dated August 21, 2001, the name of the Company was changed to `Alkem Laboratories Limited' with effect from October 26, 1988. the registered office was originally located at `Exhibition Road, Patna - 800 001, Bihar, India'. the Company filed Company Petition No. 356(17)/ ERB/ 2007 before the Company Law Board, Eastern Region Bench at Kolkata for shifting the registered office of the Company from the State of Bihar to the State of Maharashtra, as approved by a special resolution at its extra-ordinary general meeting held on January 29, 2007. The Company Law Board, Eastern Region Bench at Kolkata passed an order dated July 30, 2007 whereby it confirmed the alteration of the situation clause in the Memorandum of Association, from the State of Bihar to the State of Maharashtra. Pursuant to the order, the registered office of the Company was shifted to `Alkem House, Senapati Bapat Marg, Lower Parel, Mumbai - 400 013, Maharashtra, India' with effect from August 2, 2007. Major Events : 1973 -Incorporation of the Company. 1978 -the Company established its first plant at Taloja, Maharashtra. 1988 -the Company became a deemed public limited company. 1992 -the Company established its manufacturing facility in Mandwa, Maharashtra. This facility was converted into an API facility in 2005. 1998 -the Company established its Kachigam manufacturing facility in Gujarat. 2001 -Startronic Pharmachem Private Limited and Indo Propkem amalgamated with the Company. 2002 -the Company established its Amaliya manufacturing facility in Gujarat. 2003 -the Company set up its research and development facility at Taloja, Maharashtra. 2005 -the Company established its manufacturing facility in Baddi, Himachal Pradesh. 2006 -the anti-infective drug Taxim became the first drug in the Indian pharmaceutical industry to cross 1,000 million in terms of domestic sales in India (Source: IMS Research) 2007 -the Company established its manufacturing facility in Kumrek, Sikkim. -the Company filed its first ANDA in the United States for the drug, Amlodipine. -the Company shifted its Registered Office from Patna, Bihar to Mumbai, Maharashtra. 2009 -the Company acquired Pharmacor, a generic pharma company in Australia. 2010 -the Company acquired The PharmaNetwork, LLC, the holding company of Ascend Laboratories LLC. 2011 -the Company acquired Enzene Bio sciences Limited. 2012 -the Company acquired an API manufacturing facility in the United States. 2014 -the Company acquired the Clindac. 2015 -the Company acquired a formulation manufacturing facility in the United States. Awards and achievements: 2002 -the Company was awarded the Pharma Business and Technology Excellence Award in 2002 as 'India's Most Esteemed Pharmaceutical Company' 2004 -the product Taxim was awarded the Pharma Business and Technology Excellence Award for successful brand in 2004 2005 -the Company was awarded the Overall Performance Award for Group B at the 5th Express Pharma Awards in 2005 2009 -the Company received a certificate of appreciation for outstanding export performance in the category of formulations by the Pharmaceuticals Export Promotion Council of India, supported by Ministry of Commerce and Industry, GOI -the Company received the certificate of appreciation in the category of `Formulation Experts' by the Pharmaceuticals Export Promotion Council of India, supported by Ministry of Commerce and Industry, GOI 2013 -the Company was awarded the India's most admired pharma company award for 2013 at the 6th Annual Pharmaceutical Leadership Summit in 2013 2014 -the Product `Clavam' was awarded as the ` Brand of the Year' at the AWACS Award, 2014 2016 -Alkem's Mandva Plant successfully obtains the Establishment Inspection Report from the US FDA -Alkem receives EIR from the US FDA for its Daman formulation facility

Registered Office

MIDC, Taloja

,,,      ,

Registrar Details

Link Intime India Pvt. Ltd.